GlaxoSmithKline 2Q Revenues: $10.2 billion (-7%)   2Q Earnings: $2.1 billion (+10%)   YTD Revenues: $20.7 billion (-4%)   YTD Earnings: $4.3 billion (-2%)   Comments: Pharmaceuticals sales in the quarter were down 3% to $6.9 billion, reflecting the loss of Vesicare sales following the conclusion of the co-promotion agreement in 1Q12. Seretide/Advair sales were $2.0 billion (-5%). Lamictal sales were $232 million (+10%). Avodart sales were $311 million (+1%). Vaccines sales were $1.2 billion (-8...